false
0001677077
0001677077
2024-10-03
2024-10-03
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
___________________________________________________________________
Date of Report (Date of earliest event reported): October 3, 2024
ALZAMEND NEURO, INC.
(Exact name of registrant as specified in its charter)
| Delaware |
|
001-40483 |
|
81-1822909 |
(State or other jurisdiction of
incorporation or organization) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
3480 Peachtree Road NE, Second Floor, Suite
103, Atlanta, GA 30326
(Address of principal executive offices) (Zip Code)
(844) 722-6333
(Registrant's telephone number, including area
code)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b)
of the Act:
| Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange on which registered |
| Common Stock, $0.0001 par value |
|
ALZN |
|
The Nasdaq Capital Market |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company x
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
| ITEM 1.01 | ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT. |
On October 3, 2024, Alzamend Neuro, Inc. (the “Company”)
entered into an At-the-Market Issuance Sales Agreement (the “Sales Agreement”) with Ascendiant Capital Markets, LLC,
as sales agent (the “Agent”) to sell shares of its common stock, par value $0.0001 (the “Common Stock”),
having an aggregate offering price of up to $6.5 million (the “Shares”) from time to time, through an “at the
market offering” (the “ATM Offering”) as defined in Rule 415 under the Securities Act of 1933, as amended (the
“Securities Act”). On October 3, 2024, the Company filed a prospectus supplement with the Securities and Exchange Commission
(the “Commission”) relating to the offer and sale of up to $6.5 million in shares of common stock in the ATM Offering.
The offer and sale of the Shares will be made pursuant to the
Company’s effective “shelf” registration statement on Form S-3 and an accompanying base prospectus contained therein
(Registration Statement No. 333-273610) filed with the SEC on August 2, 2023 and declared effective by the Commission on August 10,
2023.
This Current Report on Form 8-K shall not constitute an offer
to sell or the solicitation of any offer to buy the Shares, nor shall there be any offer, solicitation or sale of the Shares in any state
in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state.
Subject to the terms and conditions of the Sales Agreement,
the Agent will use its commercially reasonable efforts to sell the Shares, based upon the Company’s instructions, consistent with
its normal trading and sales practices and applicable state and federal laws, rules and regulations and rules of the Nasdaq Stock Market.
The Company will set the parameters for sales of the Shares, including the number of Shares to be sold, the time period during which sales
are requested to be made, any limitation on the number of Shares that may be sold in one trading day, and any minimum price below which
sales may not be made. Under the Sales Agreement, the Agent may sell the Shares by any method permitted by law deemed to be an “at
the market offering,” as defined in Rule 415 of the Securities Act. The Company or the Agent may, upon written notice to the other
party in accordance with the terms of the Sales Agreement, suspend offers and sales of the Shares. The Company and the Agent each have
the right, in its sole discretion, to terminate the Sales Agreement at any time upon prior written notice pursuant to the terms and subject
to the conditions set forth in the Sales Agreement.
The foregoing description of the terms of the Sales Agreement
does not purport to be complete and is subject to, and qualified in its entirety by reference to, the Sales Agreement, which is filed
herewith as Exhibit 10.1 and is incorporated herein by reference.
The legal opinion of Olshan Frome Wolosky LLP, counsel to the
Company, relating to the legality of the issuance and sale of the Shares is filed as Exhibit 5.1 hereto.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
ALZAMEND NEURO, INC. |
|
| |
|
|
| |
|
|
| Dated: October 3, 2024 |
/s/ Henry Nisser |
|
| |
Henry Nisser
Executive Vice President and General Counsel |
|
-3-
Exhibit 5.1
October 3, 2024
Alzamend Neuro, Inc.
3480 Peachtree Road NE, Second Floor, Suite 103
Atlanta, GA 30326
Ladies and Gentlemen:
We are acting as counsel for
Alzamend Neuro, Inc., a Delaware corporation (the “Company”), in connection with the issuance and sale of up to $6.5 million
in shares (the “Shares”) of common stock, par value $0.0001 per share (the “Common Stock”), of the Company, all
of which are authorized but heretofore unissued shares to be offered and sold by the Company pursuant to the Registration Statement on
Form S-3 (Registration No. 333-273610) (the “Registration Statement”), originally filed by the Company with the U.S. Securities
and Exchange Commission (the “Commission”) under the Securities Act of 1933 (the “Act”), on August 2, 2023, which
became effective on August 10, 2023, and the related prospectus dated therein (the “Prospectus”), as supplemented by the prospectus
supplement dated October 3, 2024, relating to the offer and sale of the Shares (the “Prospectus Supplement”).
For purposes of this opinion,
we have examined such documents and reviewed such questions of law as we have considered necessary and appropriate for the purposes of
our opinion set forth below. In rendering our opinion, we have assumed the authenticity of all documents submitted to us as originals,
the genuineness of all signatures and the conformity to authentic originals of all documents submitted to us as copies. We have also assumed
that Nasdaq will approve the listing of the Shares, the legal capacity for all purposes relevant hereto of all natural persons and, with
respect to all parties to agreements or instruments relevant hereto other than the Company, that such parties had the requisite power
and authority (corporate or otherwise) to execute, deliver and perform such agreements or instruments, that such agreements or instruments
have been duly authorized by all requisite action (corporate or otherwise), executed and delivered by such parties and that such agreements
or instruments are the valid, binding and enforceable obligations of such parties. As to questions of fact material to our opinions, we
have relied upon certificates of officers of the Company and of public officials. Based upon and subject to the foregoing, we are of the
opinion that the Shares have been duly authorized and, when issued and paid for as described in the Registration Statement, the Prospectus
and the Prospectus Supplement, will be or are validly issued, fully paid and nonassessable.
We hereby consent to the filing of this opinion letter as Exhibit 5.1
to the Company’s Current Report on Form 8-K filed by the Company with the Commission on the date hereof and the incorporation thereof
in the Registration Statement and to the use of our name under the caption “Legal Matters” in the Prospectus. In giving this
consent, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Act or the
rules and regulations of the Commission promulgated thereunder.
| |
Very truly yours, |
| |
|
| |
/s/ Olshan Frome Wolosky LLP |
| |
|
| |
OLSHAN FROME WOLOSKY LLP |
Exhibit 10.1
ALZAMEND NEURO, INC.
Common Stock
(par value $0.0001 per share)
At-The-Market Issuance Sales Agreement
October 3, 2024
Ascendiant Capital Markets, LLC
110 Front Street, Suite 300
Jupiter, FL 33477
Ladies and Gentlemen:
Alzamend Neuro, Inc., a Delaware
corporation (the Company”), confirms its agreement (this “Agreement”) with Ascendiant Capital Markets,
LLC (the “Agent”), as follows:
1. Issuance
and Sale of Shares. The Company agrees to issue and sell through or to the Agent, shares (the “Placement Shares”)
of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), from time to time during the
term of this Agreement and on the terms set forth in this Agreement; provided however, that in no event will the Company issue
or sell through or to the Agent such dollar amount of Placement Shares that would exceed $6.5 million in the aggregate, subject to
General Instruction I.B.6 of Form S-3 (the “Maximum Amount”). Notwithstanding anything to the contrary contained herein,
the parties hereto agree that compliance with the limitations set forth in this Section 1 on the amount of Placement Shares issued and
sold under this Agreement will be the sole responsibility of the Company and that the Agent will have no obligation in connection with
such compliance provided the Agent follows the trading instructions provided by the Company pursuant to any Placement Notice in all material
respects. The issuance and sale of Placement Shares through or to the Agent will be effected pursuant to the Registration Statement (as
defined below) filed by the Company and declared effective by the U.S. Securities and Exchange Commission (the “SEC”),
though nothing in this Agreement will be construed as requiring the Company to use the Registration Statement to issue Common Stock. Certain
capitalized terms used in this Agreement have the meanings ascribed to them in Section 25.
The Company has filed with
the SEC, in accordance with the provisions of the Securities Act of 1933, as amended (the “Securities Act”), and the
rules and regulations thereunder (the “Securities Act Regulations”), a registration statement on Form S-3 (File No.
333-273610), including a base prospectus, relating to certain securities, including the Placement Shares, to be issued from time to time
by the Company, and which incorporates by reference documents that the Company has filed or will file in accordance with the provisions
of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations thereunder.
The Company has prepared or will prepare a prospectus supplement specifically relating to the Placement Shares (the “Prospectus
Supplement”) to the base prospectus included as part of the registration statement. The Company will furnish to the Agent, for
use by it, copies of the prospectus included as part of the registration statement, as supplemented by the Prospectus Supplement. Except
when the context otherwise requires, such registration statement, including all documents filed as part thereof or incorporated by reference
therein, and including any information contained in a Prospectus (as defined below) subsequently filed with the SEC pursuant to Rule 424(b)
under the Securities Act Regulations or deemed to be a part of the registration statement pursuant to Rule 430B of the Securities
Act Regulations, is herein called the “Registration Statement.” The base prospectus, including all documents incorporated
therein by reference, included in the Registration Statement, as it may be supplemented by the Prospectus Supplement, in the form in which
the prospectus and/or Prospectus Supplement have most recently been filed by the Company with the SEC pursuant to Rule 424(b) under
the Securities Act Regulations is herein called the “Prospectus.” Any reference herein to the Registration Statement,
the Prospectus, or any amendment or supplement thereto will be deemed to refer to and include the documents incorporated by reference
therein, and any reference herein to the terms “amend,” “amendment,” or “supplement” respecting the
Registration Statement or the Prospectus will be deemed to refer to and include the filing of any document with the SEC deemed to be incorporated
by reference therein, including in each such case filings made after the execution hereof (any such documents, collectively, the “Incorporated
Documents”).
For purposes of this Agreement,
all references to the Registration Statement, the Prospectus, or to any amendment or supplement thereto will be deemed to include the
most recent copy filed with the SEC pursuant to its Electronic Data Gathering Analysis and Retrieval System, or if applicable, the Interactive
Data Electronic Application system when used by the SEC (collectively, “EDGAR”).
2. Placements.
Each time that the Company wishes to issue and sell Placement Shares hereunder (each, a “Placement”), it will notify
the Agent by email notice (or other method mutually agreed to in writing by the parties) of the number of Placement Shares, the period
during which sales are requested to be made, any limitation on the number of Placement Shares that may be sold in any one day, and any
minimum price below which sales may not be made (a “Placement Notice”), the form of which is attached hereto as Schedule
1. The Placement Notice will originate from any of the individuals from the Company set forth on Schedule 3 (with a copy to
each of the other individuals from the Company listed on the schedule) and will be addressed to each of the individuals from the Agent
that are set forth on Schedule 3, as Schedule 3 may be amended from time to time. The Placement Notice will be effective
unless and until: (a) the Agent declines to accept the terms contained therein for any reason, in its sole discretion, which must
be evidenced by a written notice to the Company, addressed to the individuals set forth on Schedule 3 within two (2) Business Days
after receipt of such Placement Notice; (b) the entire amount of the Placement Shares thereunder have been sold; (c) the Company
suspends or terminates the Placement Notice; or (d) the Agreement has been terminated under the provisions of Section 13. The amount
of any discount, commission, or other compensation to be paid by the Company to the Agent in connection with the sale of the Placement
Shares will be calculated in accordance with the terms set forth in Schedule 2. Neither the Company nor the Agent will have any
obligation whatsoever respecting a Placement or any Placement Shares unless and until the Company delivers a Placement Notice to the Agent
and the Agent does not decline such Placement Notice pursuant to the terms set forth above, and then only upon the terms specified therein
and herein. In the event of a conflict between the terms of Sections 2, 3, and 4 of this Agreement and the terms of a Placement Notice,
the terms of the Placement Notice will control.
3. Sale
of Placement Shares by the Agent. Subject to the terms and conditions of this Agreement, the Agent, for the period specified in the
Placement Notice, will use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable state
and federal laws, rules, and regulations and the rules of the Nasdaq Stock Market (the “Exchange”), to sell the Placement
Shares in accordance with the terms of such Placement Notice. The Agent will provide written confirmation to the Company no later than
the opening of the Trading Day (as defined below) immediately following the Trading Day on which it has sold Placement Shares hereunder,
setting forth the number of Placement Shares sold on such day, the compensation payable by the Company to the Agent pursuant to Section 2
for such sales, and the Net Proceeds (as defined below) payable to the Company, with an itemization of the deductions made by the Agent
(as set forth in Section 5(b)) from the gross proceeds that it receives from such sales. Subject to the terms of the Placement
Notice, Placement Shares may be sold hereunder by any method permitted by law deemed to be an “at the market” offering as
defined in Rule 415(a)(1)(x) and Rule 415(a)(4) of the Securities Act Regulations, including sales made directly on the Exchange
or on any other existing trading market for the Common Stock, to or through a market maker or directly to the Placement Agent as principal
in negotiated transactions. Subject to the terms of a Placement Notice, the Agent may also sell Placement Shares by any other method permitted
by law, including in privately negotiated transactions, with the Company’s consent. “Trading Day” means any day
on which Common Stock is purchased and sold on the Exchange.
4. Suspension
of Sales. The Company or the Agent may, upon notice to the other party in writing (including by email correspondence to each of the
individuals of the other party set forth on Schedule 3, if receipt of such correspondence is actually acknowledged by any of the
individuals to whom the notice is sent, other than via auto-reply) or by telephone (confirmed immediately by verifiable email correspondence
to each of the individuals of the other party set forth on Schedule 3), suspend any sale of Placement Shares; provided, however,
that such suspension will not affect or impair any party’s obligations respecting any Placement Shares sold hereunder prior to the
receipt of such notice. Notwithstanding anything herein to the contrary, the obligations under Section 7(l), 7(m), and 7(n) with
respect to delivery of certificates, opinions and comfort letters to the Agent shall not apply while a suspension of sales under this
Section 4 is in effect. Each of the parties agrees that no such notice under this Section 4 will be effective against any
other party unless it is made to one of the individuals named on Schedule 3 hereto, as such schedule may be amended from time to
time.
5. Sale
and Delivery to the Agent; Settlement.
(a) Sale
of Placement Shares. On the basis of the representations and warranties herein contained and subject to the terms and conditions
herein set forth, upon delivery of a Placement Notice, and unless the sale of the Placement Shares described therein has been declined,
suspended, or otherwise terminated in accordance with the terms of this Agreement, the Agent, for the period specified in the Placement
Notice, will use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable state and federal
laws, rules and regulations and the rules of the Exchange to sell such Placement Shares up to the amount specified, and otherwise in accordance
with the terms of such Placement Notice. The Company acknowledges and agrees that: (i) there can be no assurance that the Agent will
be successful in selling Placement Shares; (ii) the Agent will not incur any liability or obligation to the Company or any other
Person (as defined herein) for a failure to sell Placement Shares for any reason other than a failure by the Agent to use its commercially
reasonable efforts consistent with its normal trading and sales practices and applicable law and regulations to sell such Placement Shares
as required under this Agreement; and (iii) the Agent will not be under any obligation to purchase Placement Shares on a principal
basis pursuant to this Agreement, except as otherwise agreed by the Agent and the Company.
(b) Settlement
of Placement Shares. Unless otherwise specified in the applicable Placement Notice, settlement for sales of Placement Shares
will occur on the second Trading Day (or such earlier day as is industry practice for regular-way trading) following the date on which
such sales are made (each, a “Settlement Date”). The Agent shall notify the Company of each sale of Placement Shares
no later than the opening day following the Trading Day that the Agent sold Placement Shares. The amount of proceeds to be delivered to
the Company on a Settlement Date against receipt of the Placement Shares sold (the “Net Proceeds”) will be equal to
the aggregate sales price received by the Agent, after deduction for the Agent’s commission, discount, or other compensation
for such sales payable by the Company pursuant to Section 2 hereof.
(c) Delivery
of Placement Shares. Before each Settlement Date, the Company will, or will cause its transfer agent to, electronically transfer an
agreed-upon amount of the Placement Shares being sold by crediting the Agent’s account or its designee’s account (provided
the Agent shall have given the Company written notice of such designee a reasonable period of time prior to the Settlement Date) at The
Depository Trust Company through its Deposit and Withdrawal at Custodian System or by such other means of delivery as may be mutually
agreed upon by the parties hereto, which in all cases will be freely tradable, transferable, registered shares in good deliverable form.
On each Settlement Date, the Agent will deliver the related Net Proceeds in same-day funds to an account designated by the Company on,
or prior to, the Settlement Date. The Agent is not obligated to sell any of the Placement Shares unless they are first deposited in the
Agent’s account or its designee’s account. The Company agrees that if the Company or its transfer agent defaults in its obligation
to deliver Placement Shares before a Settlement Date through no fault of the Agent that, in addition to and in no way limiting the rights
and obligations set forth in Section 11(a) hereto, it will hold the Agent harmless against any loss, claim, damage, or expense
(including reasonable and documented legal fees and expenses) arising out of or in connection with such default by the Company or its
transfer agent (if applicable).
(d) Limitations
on Offering Size. Under no circumstances will the Company cause or request the offer or sale of any Placement Shares if, after
giving effect to the sale of such Placement Shares, the aggregate gross sales proceeds of Placement Shares sold pursuant to this Agreement
would exceed the lesser of: (i) together with all sales of Placement Shares under this Agreement, the Maximum Amount; or (ii) the
amount authorized from time to time to be issued and sold under this Agreement by the Company’s board of directors, a duly authorized
committee thereof, or a duly authorized executive committee, and notified to the Agent in writing. Under no circumstances will the Company
cause or request the offer or sale of any Placement Shares pursuant to this Agreement at a price lower than the minimum price authorized
from time to time by the Company’s board of directors, a duly authorized committee thereof, or a duly authorized executive committee,
and notified to the Agent in writing.
6. Representations
and Warranties of the Company. The Company represents and warrants to, and agrees with, the Agent that as of the date of this Agreement
and as of each Applicable Time (as defined below), unless such representation, warranty or agreement specifies a different date or time:
(a) Registration
Statement and Prospectus. The Company and, assuming no act or omission on the part of the Agent that would make such statement untrue,
the transactions contemplated by this Agreement meet the requirements for and comply with the conditions for the use of Form S-3 under
the Securities Act. The Registration Statement has been filed with the SEC and has been declared effective under the Securities Act. The
Prospectus Supplement will name the Agent as the agent in the section entitled “Plan of Distribution.” The Company has not
received, and has no notice of, any order of the SEC preventing or suspending the use of the Registration Statement or threatening or
instituting proceedings for that purpose. The Registration Statement and the offer and sale of Placement Shares as contemplated hereby
meet the requirements of Rule 415 under the Securities Act and comply in all material respects with said Rule. Any statutes, regulations,
contracts, or other documents that are required to be described in the Registration Statement or the Prospectus or to be filed as exhibits
to the Registration Statement have been so described or filed. Copies of the Registration Statement, the Prospectus, and any such amendments
or supplements and all documents incorporated by reference therein that were filed with the SEC on or prior to the date of this Agreement
have been delivered, or are available through EDGAR, to the Agent and its counsel. The Company has not distributed and, prior to the later
to occur of each Settlement Date and completion of the distribution of the Placement Shares, will not distribute any offering material
in connection with the offering or sale of the Placement Shares other than the Registration Statement and the Prospectus and any Issuer
Free Writing Prospectus (as defined below) to which the Agent has consented, which consent shall not be unreasonably withheld or delayed.
The Common Stock is currently listed on the Exchange under the trading symbol “ALZN.” Except as disclosed in the Registration
Statement, including the Incorporated Documents, the Company has not, in the six months preceding the date hereof, received notice from
the Exchange to the effect that the Company is not in compliance with the Exchange’s listing requirements. Except as disclosed in
the Registration Statement, including the Incorporated Documents, or the Prospectus, the Company believes that it will be able to comply
with the Exchange listing requirements.
(b) No
Misstatement or Omission. The Registration Statement, when it became effective, and the Prospectus, and any amendment or supplement
thereto, on the date of such Prospectus or amendment or supplement, conformed and will conform in all material respects with the requirements
of the Securities Act. At each Settlement Date, the Registration Statement and the Prospectus, as of such date, will conform in all material
respects with the requirements of the Securities Act. The Registration Statement, when it became effective, did not contain an untrue
statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein
not misleading. The Prospectus and any amendment and supplement thereto, on the date thereof and at each Applicable Time (defined below),
did not and will not include an untrue statement of a material fact or omit to state a material fact necessary to make the statements
therein, in light of the circumstances under which they were made, not misleading. The documents incorporated by reference in the Prospectus
or any Prospectus Supplement did not, and any further documents incorporated by reference therein will not, when filed with the SEC, contain
an untrue statement of a material fact or omit to state a material fact required to be stated in such document or necessary to make the
statements in such document, in light of the circumstances under which they were made, not misleading. The foregoing will not apply to
statements in, or omissions from, any such document made in reliance upon, and in conformity with, information furnished to the Company
by the Agent specifically for use in the preparation thereof.
(c) Conformity
with Securities Act and Exchange Act. The Incorporated Documents, when such documents were or are filed with the SEC under the Securities
Act or the Exchange Act, or became or become effective under the Securities Act, as the case may be, conformed or will conform in all
material respects with the requirements of the Securities Act and the Exchange Act, as applicable.
(d) Financial
Information. The consolidated financial statements of the Company included or incorporated by reference in the Registration Statement,
the Prospectus, and the Issuer Free Writing Prospectuses, if any, together with the related notes and schedules, complied as to form
in all material respects with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto
as in effect as of the time of filing. Such financial statements have been prepared in accordance with generally accepted accounting
principles, consistently applied, during the periods involved (except: (i) as may be otherwise indicated in such financial statements
or the notes thereto; or (ii) in the case of unaudited interim statements, to the extent they may exclude footnotes or may be condensed
or summary statements) and fairly present in all material respects the consolidated financial position of the Company as of the dates
indicated and the consolidated results of operations and cash flows of the Company for the periods specified (subject, in the case of
unaudited statements, to normal year-end audit adjustments that will not be material, either individually or in the aggregate); the other
financial and statistical data respecting the Company contained or incorporated by reference in the Registration Statement, the Prospectus,
and the Issuer Free Writing Prospectuses, if any, are accurately and fairly presented and prepared in all material respects on a basis
consistent with the financial statements and books and records of the Company; there are no financial statements (historical or pro forma)
that are required to be included or incorporated by reference in the Registration Statement or the Prospectus that are not included or
incorporated by reference as required; the Company does not have any material liabilities or obligations, direct or contingent (including
any off-balance sheet obligations), not described in the Registration Statement (including the exhibits thereto) and the Prospectus that
are required to be described in the Registration Statement or the Prospectus (including exhibits thereto and Incorporated Documents);
and all disclosures contained or incorporated by reference in the Registration Statement, the Prospectus, and the Issuer Free Writing
Prospectuses, if any, regarding “non-GAAP financial measures” (as such term is defined by the rules and regulations of the
SEC) comply in all material respects with Regulation G of the Exchange Act and Item 10 of Regulation S-K under the Securities Act, to
the extent applicable.
(e) Conformity
with EDGAR Filing. The Prospectus delivered to the Agent for use in connection with the sale of the Placement Shares pursuant to this
Agreement will be identical to the versions of the Prospectus created to be transmitted to the SEC for filing via EDGAR, except to the
extent permitted by Regulation S-T.
(f) Organization.
The Company is duly organized, validly existing as a corporation, and in good standing under the laws of its jurisdiction of incorporation,
except where the failure to be in good standing would not, individually or in the aggregate, have a Material Adverse Effect (as defined
below) or reasonably be expected to have a Material Adverse Effect. The Company is duly qualified as a foreign corporation for transaction
of business and in good standing under the laws of each other jurisdiction in which its ownership or lease of property or the conduct
of its businesses requires such qualification, and has all corporate power and authority necessary to own or hold its properties and to
conduct its businesses as described in the Registration Statement and the Prospectus, except where the failure to be so qualified or in
good standing or have such power or authority would not, individually or in the aggregate, have a material adverse effect or reasonably
be expected to have a material adverse effect on the assets, business, operations, earnings, properties, condition (financial or otherwise),
prospects, stockholders’ equity, or results of operations of the Company taken as a whole, or prevent or materially interfere with
consummation of the transactions contemplated hereby (a “Material Adverse Effect”).
(g) Subsidiaries.
The Company has no subsidiaries, whether as determined pursuant to Rule 1-02(w) of Regulation S-X or otherwise.
(h) No
Violation or Default. The Company is not: (i) in violation of its charter or bylaws or similar organizational documents; (ii) in
default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due performance
or observance of any term, covenant, or condition contained in any indenture, mortgage, deed of trust, loan agreement, or other agreement
or instrument to which the Company is a party, by which the Company is bound, or to which any of the property or assets of the Company
is subject; or (iii) in violation of any law or statute or any judgment, order, rule, or regulation of any court, arbitrator, or
governmental or regulatory authority, except, in the case of each of clauses (ii) and (iii) above, for any such violation or default that
would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. Except as described in the Prospectus,
the Prospectus Supplement, or the Incorporated Documents, to the Company’s knowledge, no other party under any material contract
or other agreement to which it is a party is in default in any respect thereunder where such default would reasonably be expected to have
a Material Adverse Effect.
(i) No
Material Adverse Change. Subsequent to the respective dates as of which information is given in the Registration Statement and the
Prospectus (including any Incorporated Documents), there has not been: (i) any Material Adverse Effect, or any development involving
a prospective Material Adverse Effect, in or affecting the business, properties, management, financial, condition (financial or otherwise),
results of operations, or prospects of the Company taken as a whole; (ii) any transaction that is material to the Company taken as
a whole; (iii) any obligation or liability, direct or contingent (including any off-balance sheet obligations), incurred by the Company,
that is material to the Company taken as a whole; (iv) any material change in the capital stock (other than as a result of the sale
of Placement Shares or other than as described in a proxy statement filed on Schedule 14A or a Registration Statement on Form S-4 and
otherwise publicly announced) or outstanding long-term indebtedness of the Company; or (v) any dividend or distribution of any kind
declared, paid, or made on the capital stock of the Company, other than in each case above, in the ordinary course of business or as otherwise
disclosed in the Registration Statement or Prospectus (including any document deemed incorporated by reference therein).
(j) Capitalization.
The issued and outstanding shares of capital stock of the Company have been validly issued, are fully paid, and nonassessable. The Company
has an authorized, issued, and outstanding capitalization as set forth in the Registration Statement or the Prospectus as of the dates
referred to therein (other than the grant of shares of Common Stock, options or restricted stock under the Company’s existing equity
incentive plans, or changes in the number of outstanding Common Stock of the Company due to the issuance of shares upon the exercise or
conversion of securities exercisable for, or convertible into, Common Stock outstanding on the date hereof or as a result of the issuance
of Placement Shares), and such authorized capital stock conforms to the description thereof set forth in the Registration Statement and
the Prospectus. The description of the Common Stock in the Registration Statement and the Prospectus is complete and accurate in all material
respects. Except as disclosed in or contemplated by the Registration Statement, the Prospectus, and the Incorporated Documents, as of
the date referred to therein, the Company did not have reserved or available for issuance any shares of Common Stock in respect of options,
any rights or warrants to subscribe for, any securities or obligations convertible into or exchangeable for, or any contracts or commitments
to issue or sell, any shares of capital stock or other securities.
(k) Authorization;
Enforceability. The Company has full legal right, power, and authority to enter into this Agreement and perform the transactions contemplated
hereby. This Agreement has been duly authorized, executed, and delivered by the Company and is a legal, valid, and binding agreement of
the Company enforceable in accordance with its terms, except to the extent that: (i) enforceability may be limited by bankruptcy,
insolvency, reorganization, moratorium, or similar laws affecting creditors’ rights generally and by general equitable principles;
and (ii) the indemnification and contribution provisions of Section 11 hereof may be limited by federal or state securities
laws and public policy considerations in respect thereof.
(l) Authorization
of Placement Shares. The Placement Shares, when issued and delivered pursuant to the terms approved by the board of directors of the
Company or a duly authorized committee thereof, or a duly authorized executive committee, against payment therefor as provided herein,
will be duly and validly authorized and issued and fully paid and nonassessable, free and clear of any pledge, lien, encumbrance, security
interest, or other claim (other than any pledge, lien, encumbrance, security interest, or other claim arising from an act or omission
of any Agent or a purchaser), including any statutory or contractual preemptive rights, resale rights, rights of first refusal, or other
similar rights, and will be registered pursuant to Section 12 of the Exchange Act. The Placement Shares, when issued, will conform in
all material respects to the description thereof set forth in or incorporated into the Prospectus.
(m) No
Consents Required. No consent, approval, authorization, order, registration, or qualification of or with any court or arbitrator or
any governmental or regulatory authority having jurisdiction over the Company is required for the execution, delivery, and performance
by the Company of this Agreement, and the issuance and sale by the Company of the Placement Shares as contemplated hereby, except for
such consents, approvals, authorizations, orders, and registrations or qualifications as may be required under applicable state securities
laws or by the bylaws and rules of the Exchange in connection with the sale of the Placement Shares by the Agent.
(n) No
Preferential Rights. Except as set forth in the Registration Statement or the Prospectus: (i) no person, as such term is defined
in Rule 1-02 of Regulation S-X promulgated under the Securities Act (each, a “Person”), has the right, contractual
or otherwise, to cause the Company to issue or sell to such Person any Common Stock or shares of any other capital stock or other securities
of the Company (other than upon the exercise of options or warrants to purchase Common Stock or upon the exercise of options that may
be granted from time to time under the Company’s stock option plans); (ii) no Person has any preemptive rights, rights of
first refusal, or any other rights (whether pursuant to a “poison pill” provision or otherwise) to purchase any Common Stock
or shares of any other capital stock or other securities of the Company from the Company that have not been duly waived respecting the
offering contemplated hereby; (iii) no Person has the right to act as an underwriter or as a financial advisor to the Company in
connection with the offer and sale of the Placement Shares; and (iv) no Person has the right, contractual or otherwise, to require
the Company to register under the Securities Act any Common Stock or shares of any other capital stock or other securities of the Company,
or to include any such shares or other securities in the Registration Statement or the offering contemplated thereby, whether as a result
of the filing or effectiveness of the Registration Statement or the sale of the Placement Shares as contemplated thereby or otherwise,
except for such rights as have been waived on or prior to the date hereof.
(o) Independent
Public Accountant. Haskell & White LLP (the “Accountants”), whose report on the consolidated financial statements
of the Company are filed with the SEC as part of the Company’s most recent Annual Report on Form 10-K and incorporated by reference
into the Registration Statement, is and, during the periods covered by its report, was an independent registered public accounting firm
within the meaning of the Securities Act and the Public Company Accounting Oversight Board (United States). To the Company’s knowledge,
the Accountants are not in violation of the auditor independence requirements of the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley
Act”) respecting the Company.
(p) Enforceability
of Agreements. To the Company’s knowledge, all agreements between the Company and third parties expressly referenced in the
Prospectus, other than such agreements that have expired by their terms or whose termination is disclosed in documents filed by the Company
on EDGAR, are legal, valid, and binding obligations of the Company enforceable in accordance with its terms, except to the extent that:
(i) enforceability may be limited by bankruptcy, insolvency, reorganization, moratorium, or similar laws affecting creditors’
rights generally and by general equitable principles; and (ii) the indemnification provisions of certain agreements may be limited
be federal or state securities laws or public policy considerations in respect thereof, except for any unenforceability that, individually
or in the aggregate, would not reasonably be expected to have a Material Adverse Effect.
(q) No
Litigation. Except as set forth in the Registration Statement or the Prospectus: (i) there are no legal, governmental, or regulatory
actions, suits, or proceedings pending or, to the Company’s knowledge, any legal, governmental, or regulatory investigations to
which the Company or any of its directors, officers, or controlling Persons is a party or to which any property of the Company is the
subject that, individually or in the aggregate, if determined adversely to the Company, would reasonably be expected to have a Material
Adverse Effect or materially and adversely affect the ability of the Company to perform its obligations under this Agreement; (ii) to
the Company’s knowledge, no actions, suits, or proceedings are threatened or contemplated by any governmental or regulatory authority
or threatened by others against the Company or any of its directors, officers, or controlling Persons that, individually or in the aggregate,
if determined adversely to the Company, would reasonably be expected to have a Material Adverse Effect; (iii) there are no current
or pending legal, governmental, or regulatory, actions, suits, proceedings or, to the Company’s knowledge, investigations that are
required under the Securities Act to be described in the Prospectus that are not described in the Prospectus; and (iv) there are
no contracts or other documents that are required under the Securities Act to be filed as exhibits to the Registration Statement that
are not so filed.
(r) Licenses
and Permits. Except as set forth in the Registration Statement or the Prospectus, the Company possesses or has obtained all licenses,
certificates, consents, orders, approvals, permits, and other authorizations issued by, and has made all declarations and filings with,
the appropriate federal, state, local, or foreign governmental or regulatory authorities that are necessary for the ownership or lease
of its properties or the conduct of its businesses as described in the Registration Statement and the Prospectus (the “Permits”),
except where the failure to possess, obtain, or make the same would not, individually or in the aggregate, reasonably be expected to have
a Material Adverse Effect. Except as disclosed in the Registration Statement or the Prospectus, the Company has not received written notice
of any proceeding relating to revocation or modification of any such Permit or have any reason to believe that such Permit will not be
renewed in the ordinary course, except when the failure to obtain any such renewal would not, individually or in the aggregate, reasonably
be expected to have a Material Adverse Effect.
(s) S-3
Eligibility. (i) At the time of filing the Registration Statement; and (ii) if applicable, at the time of the most recent
amendment thereto for the purposes of complying with Section 10(a)(3) of the Securities Act (whether such amendment was by post-effective
amendment, incorporated report filed pursuant to Section 13 or 15(d) of the Exchange Act, or form of prospectus), the Company met the
then-applicable requirements for use of Form S-3 under the Securities Act, including compliance with General Instruction I.B.6 of Form
S-3, for the sale of up to the Maximum Amount of Placement Shares.
(t) No
Material Defaults. Except as set forth in the Registration Statement and Prospectus, the Company has not defaulted on any installment
on indebtedness for borrowed money or on any rental on one or more long-term leases, which defaults, individually or in the aggregate,
would reasonably be expected to have a Material Adverse Effect. Except as set forth in the Registration Statement and Prospectus, the
Company has not filed a report pursuant to Section 13(a) or 15(d) of the Exchange Act since the filing of its last Annual Report on Form
10-K, indicating that it: (i) has failed to pay any dividend or sinking fund installment on preferred stock; or (ii) has defaulted
on any installment on indebtedness for borrowed money or on any rental on one or more long-term leases, which defaults, individually or
in the aggregate, could reasonably be expected to have a Material Adverse Effect.
(u) Certain
Market Activities. Neither the Company, nor, to the Company’s knowledge, any of its directors, officers, or controlling Persons
has taken, directly or indirectly, any action designed, or that has constituted or might reasonably be expected to cause or result in,
under the Exchange Act or otherwise, the stabilization or manipulation of the price of any security of the Company to facilitate the sale
or resale of the Placement Shares.
(v) Broker-Dealer
Relationships. Neither the Company nor any related entity: (i) is required to register as a “broker” or “dealer”
in accordance with the provisions of the Exchange Act; or (ii) directly or indirectly through one or more intermediaries, control
or is a “person associated with a member” or “associated person of a member” (within the meaning set forth in
the FINRA rules).
(w) No
Reliance. The Company has not relied upon the Agent or legal counsel for the Agent for any legal, tax, or accounting advice in connection
with the offering and sale of the Placement Shares.
(x) Taxes.
The Company has filed all federal, state, local, and foreign tax returns that have been required to be filed and paid all taxes shown
thereon through the date hereof, to the extent that such taxes have become due and are not being contested in good faith, except when
the failure to do so would not reasonably be expected to have a Material Adverse Effect. Except as otherwise disclosed in or contemplated
by the Registration Statement or the Prospectus, no tax deficiency has been determined adversely to the Company has had, or would reasonably
be expected to have, individually or in the aggregate, a Material Adverse Effect. The Company has no knowledge of any federal, state,
or other governmental tax deficiency, penalty, or assessment that has been or might be asserted or threatened against it that could reasonably
be expected to have a Material Adverse Effect.
(y) Title
to Real and Personal Property. The Company has good title to all of its real and personal property owned by it that are material to
the business of the Company, in each case free and clear of all liens, encumbrances, and defects, except as described in the Registration
Statement and Prospectus or that do not materially affect the value of the properties of the Company, and do not interfere in any material
respect with the use made and proposed to be made of such properties by the Company; and all of the leases, subleases, and other rights
under which the Company holds or uses properties described in the Registration Statement and Prospectus are in full force and effect,
with such exceptions as would not reasonably be expected to have a Material Adverse Effect, and the Company has not received any written
notice of any material claim of any sort that has been asserted by anyone adverse to the rights of the Company under any of the leases,
subleases, and other rights mentioned above, or affecting or questioning the rights of the Company to the continued possession or use
of the leased or subleased premises or the premises granted by leases, subleases, and other rights. The Company has the consents, easements,
rights-of-way, or licenses from any Person as are necessary to enable it to conduct its business in the manner described in the Registration
Statement and the Prospectus, subject to such qualifications as may be set forth in the Registration Statement and the Prospectus, and
except for the consents, easements, rights-of-way, or licenses the lack of which would not have, individually or in the aggregate, a Material
Adverse Effect.
(z) Intellectual
Property. Except as set forth in the Registration Statement or the Prospectus, to the Company’s knowledge, the Company owns
or possesses adequate enforceable rights to use all patents, patent applications, trademarks (both registered and unregistered), service
marks, trade names, trademark registrations, service mark registrations, copyrights, licenses, and know-how (including trade secrets and
other unpatented and/or unpatentable proprietary or confidential information, systems, or procedures) (collectively, the “Intellectual
Property”), necessary for the conduct of its businesses as conducted as of the date hereof, except to the extent that the failure
to own or possess adequate rights to use such Intellectual Property would not, individually or in the aggregate, reasonably be expected
to have a Material Adverse Effect; except as disclosed in writing to the Agent, the Company has not received any written notice of any
claim of infringement or conflict that asserted Intellectual Property rights of others, which infringement or conflict, if the subject
of an unfavorable decision, would result in a Material Adverse Effect; there are no pending, or to the Company’s knowledge, threatened
judicial proceedings or interference proceedings against the Company challenging the Company’s rights in or to or the validity of
the scope of any of the Company’s material patents, patent applications, or proprietary information; to the Company’s knowledge,
no other entity or individual has any right or claim in any of the Company’s owned, material patents, patent applications, or any
patent to be issued therefrom by virtue of any contract, license, or other agreement entered into between such entity or individual and
the Company or by any non-contractual obligation of the Company, other than by written licenses granted by the Company; the Company has
not received any written notice of any claim challenging the rights of the Company in or to any Intellectual Property owned, licensed,
or optioned by the Company that, if the subject of an unfavorable decision, would result in a Material Adverse Effect.
(aa) Environmental
Laws. Except as set forth in the Registration Statement or the Prospectus, the Company: (i) is in compliance with any and all
applicable federal, state, local, and foreign laws, rules, regulations, decisions, and orders relating to the protection of human health
and safety, the environment, hazardous or toxic substances or wastes, pollutants, or contaminants (collectively, “Environmental
Laws”); (ii) has received and is in compliance with all permits, licenses, or other approvals required of it under applicable
Environmental Laws to conduct its businesses as described in the Registration Statement and the Prospectus; (iii) has not received
written notice of any actual or potential liability for the investigation or remediation of any disposal or release of hazardous or toxic
substances or wastes, pollutants, or contaminants, except, in the case of any of clauses (i), (ii), or (iii) above, for any such failure
to comply or failure to receive required permits, licenses, other approvals or liability as would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect; and (iv) there are no costs or liabilities arising under Environmental
Laws respecting the operation of the Company’s properties (including any capital or operating expenditures required for clean-up
or closure of the properties, compliance with Environmental Laws, any permit, license, or approval or any related legal constraints or
operating activities, and any potential liabilities of third parties assumed under contract by the Company that would reasonably be expected,
individually or in the aggregate, to have a Material Adverse Effect.
(bb) Disclosure
Controls. Except as set forth in the Registration Statement or the Prospectus, the Company maintains a system of internal accounting
controls designed to provide reasonable assurance that: (i) transactions are executed in accordance with management’s general
or specific authorizations; (ii) transactions are recorded as necessary to permit preparation of financial statements in conformity
with generally accepted accounting principles and to maintain asset accountability; (iii) access to assets is permitted only in accordance
with management’s general or specific authorization; and (iv) the recorded accountability for assets is compared with the existing
assets at reasonable intervals and appropriate action is taken respecting any differences. The Company is not aware of any material weaknesses
in its internal control over financial reporting (other than as set forth in the Prospectus). Since the date of the latest audited financial
statements of the Company included in the Prospectus, there has been no change in the Company’s internal control over financial
reporting that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial
reporting (other than as set forth in the Prospectus). Except as set forth in the Registration Statement or the Prospectus, the Company
has established disclosure controls and procedures (as defined in Exchange Act Rules 13a-15 and 15d-15) for the Company and designed such
disclosure controls and procedures to provide reasonable assurance that material information relating to the Company is made known to
the certifying officers by others within those entities, particularly during the period in which the Company’s Annual Report on
Form 10-K or Quarterly Report on Form 10-Q, as the case may be, is being prepared. The Company’s certifying officers have evaluated
the effectiveness of the Company’s controls and procedures as of a date within 90 days prior to the filing date of the Form 10-K
for the fiscal year most recently ended (such date, the “Evaluation Date”). The Company will present in its Form 10-K
for the fiscal year most recently ended the conclusions of the certifying officers about the effectiveness of the disclosure controls
and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no significant changes
in the Company’s internal controls (as such term is defined in Item 307(b) of Regulation S-K under the Securities Act).
(cc) Sarbanes-Oxley.
There is and has been no failure on the part of the Company or, to the knowledge of the Company, any of the Company’s directors
or officers, in their capacities as such, to comply in all material respects with any applicable provisions of the Sarbanes-Oxley Act
and the rules and regulations promulgated thereunder. Each of the principal executive officer and the principal financial officer of the
Company (or each former principal executive officer of the Company and each former principal financial officer of the Company as applicable)
has made all certifications required by Sections 302 and 906 of the Sarbanes-Oxley Act respecting all reports, schedules, forms, statements,
and other documents required to be filed by it or furnished by it to the SEC. For purposes of the preceding sentence, “principal
executive officer” and “principal financial officer” will have the meanings given to such terms in the Sarbanes-Oxley
Act.
(dd) Finder’s
Fees. The Company has not incurred any liability for any finder’s fees, brokerage commissions, or similar payments in connection
with the transactions herein contemplated, except as may otherwise exist respecting the Agent pursuant to this Agreement.
(ee) Labor
Disputes. No labor disturbance by or dispute with employees of the Company exists or, to the knowledge of the Company, is threatened
that would reasonably be expected to result in a Material Adverse Effect.
(ff) Investment
Company Act. The Company neither is nor, after giving effect to the offering and sale of the Placement Shares, will be an “investment
company” or an entity “controlled” by an “investment company,” as such terms are defined in the Investment
Company Act of 1940, as amended (the “Investment Company Act”).
(gg) Operations.
The operations of the Company are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting
requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions
to which the Company are subject, the rules and regulations thereunder, and any related or similar rules, regulations, or guidelines,
issued, administered, or enforced by any governmental agency having jurisdiction over the Company (collectively, the “Money Laundering
Laws”), except as would not reasonably be expected to result in a Material Adverse Effect; and no action, suit, or proceeding
by or before any court or governmental agency, authority, or body or any arbitrator involving the Company respecting the Money Laundering
Laws is pending or, to the knowledge of the Company, threatened.
(hh) Off-Balance
Sheet Arrangements. There are no transactions, arrangements, and other relationships between and/or among the Company, and/or, to
the knowledge of the Company, any of its affiliates and any unconsolidated entity, including any structural finance, special purpose,
or limited purpose entity (each, an “Off Balance Sheet Transaction”) that could reasonably be expected to affect materially
the Company’s liquidity or the availability of or requirements for its capital resources, including those Off Balance Sheet Transactions
described in the SEC’s Statement about Management’s Discussion and Analysis of Financial Conditions and Results of Operations
(Release Nos. 33-8056; 34-45321; FR-61), required to be described in the Prospectus that have not been described as required.
(jj) Underwriter
Agreements. The Company is not a party to any agreement with an agent or underwriter for any other “at-the-market” or
continuous equity transaction.
(jj) ERISA.
To the knowledge of the Company: (i) each material employee benefit plan, within the meaning of Section 3(3) of the Employee Retirement
Income Security Act of 1974, as amended (“ERISA”), that is maintained, administered, or contributed to by the Company
(other than a Multiemployer Plan, within the meaning of Section 3(37) of ERISA) for employees or former employees of the Company has been
maintained in material compliance with its terms and the requirements of any applicable statutes, orders, rules, and regulations, including
ERISA and the Internal Revenue Code of 1986, as amended (the “Code”); (ii) no prohibited transaction, within the
meaning of Section 406 of ERISA or Section 4975 of the Code, has occurred respecting any such plan (excluding transactions effected pursuant
to a statutory or administrative exemption); and (iii) for each such plan that is subject to the funding rules of Section 412 of
the Code or Section 302 of ERISA, no “accumulated funding deficiency” as defined in Section 412 of the Code has been incurred,
whether or not waived, and the fair market value of the assets of each such plan (excluding for these purposes accrued but unpaid contributions)
equals or exceeds the present value of all benefits accrued under such plan determined using reasonable actuarial assumptions, other than,
in the case of (i), (ii), and (iii) above, as would not reasonably be expected to have a Material Adverse Effect.
(kk) Margin
Rules. Neither the issuance, sale, and delivery of the Placement Shares nor the application of the proceeds thereof by the Company
as described in the Registration Statement and the Prospectus will violate Regulation T, U, or X of the Board of Governors of the Federal
Reserve System or any other regulation of such Board of Governors.
(ll) Insurance.
The Company carries, or is covered by, insurance in such amounts and covering such risks as the Company reasonably believes are adequate
for the conduct of its properties and as is customary for companies of similar size engaged in similar businesses in similar industries.
(mm) No Improper
Practices. (i) Neither the Company nor, to the Company’s knowledge, any of its executive officers has, in the past five
years, made any unlawful contributions to any candidate for any political office (or failed fully to disclose any contribution in violation
of law) or made any contribution or other payment to any official of, or candidate for, any federal, state, municipal, or foreign office
or other Person charged with similar public or quasi-public duty in violation of any law or of the character required to be disclosed
in the Prospectus; (ii) no relationship, direct or indirect, exists between or among the Company or, to the Company’s knowledge,
any affiliate thereof, on the one hand, and the directors, officers and stockholders of the Company, on the other hand, that is required
by the Securities Act to be described in the Registration Statement and the Prospectus that is not so described; (iii) no relationship,
direct or indirect, exists between or among the Company or any affiliate thereof, on the one hand, and the directors, officers, stockholders,
or directors of the Company, on the other hand, that is required by the rules of FINRA to be described in the Registration Statement and
the Prospectus that is not so described; (iv) except as described in the Prospectus, there are no material outstanding loans or advances
or material guarantees of indebtedness by the Company to or for the benefit of any of its officers or directors or any of the members
of the families of any of them; and (v) the Company has not offered, or caused any placement agent to offer, Common Stock to any
Person with the intent to influence unlawfully: (1) a customer or supplier of the Company to alter the customer’s or supplier’s
level or type of business with the Company; or (2) a trade journalist or publication to write or publish favorable information about
the Company or any of its products or services; and (vi) neither the Company nor, to the Company’s knowledge, any employee
or agent of the Company has made any payment of funds of the Company or received or retained any funds in violation of any law, rule,
or regulation (including the Foreign Corrupt Practices Act of 1977), which payment, receipt, or retention of funds is of a character required
to be disclosed in the Registration Statement or the Prospectus.
(nn) Status
under the Securities Act. The Company was not and is not an ineligible issuer as defined in Rule 405 under the Securities Act at
the times specified in Rules 164 and 433 under the Securities Act in connection with the offering of the Placement Shares.
(oo) No
Misstatement or Omission in an Issuer Free Writing Prospectus. Each Issuer Free Writing Prospectus, as of its issue date and as of
each Applicable Time (as defined in Section 25 below), did not, does not and will not include any information that conflicted,
conflicts or will conflict with the information contained in the Registration Statement or the Prospectus, including any incorporated
document deemed to be a part thereof that has not been superseded or modified. The foregoing sentence does not apply to statements in
or omissions from any Issuer Free Writing Prospectus based upon and in conformity with written information furnished to the Company by
the Agent specifically for its use therein.
(pp) No Conflicts.
None of the execution of this Agreement; the issuance, offering, or sale of the Placement Shares; the consummation of any of the transactions
contemplated herein; or the compliance by the Company with the terms and provisions hereof will conflict with or result in a breach of
any of the terms and provisions of; constitute or will constitute a default under; or has resulted in or will result in the creation or
imposition of any lien, charge, or encumbrance upon any property or assets of the Company pursuant to the terms of any contract or other
agreement to which the Company may be bound or to which any of the property or assets of the Company is subject, except: (i) such
conflicts, breaches, or defaults as may have been waived; and (ii) such conflicts, breaches, and defaults that would not reasonably
be expected to have a Material Adverse Effect; nor will such action result in any material violation of the provisions of the organizational
or governing documents of the Company or in any material violation of the provisions of any statute or any order, rule, or regulation
applicable to the Company or of any court or of any federal, state, or other regulatory authority or other government body having jurisdiction
over the Company, except where such violation would not reasonably be expected to have a Material Adverse Effect.
(qq) Regulatory
Compliance.
(i) Neither
the Company nor, to the Company’s knowledge, any director, officer, employee, agent, affiliate, or representative of the Company,
is a government, individual, or entity that is owned or controlled by any director, officer, employee, agent, affiliate, or representative
of the Company that is:
(1) the
subject of any sanctions administered or enforced by the U.S. Department of Treasury’s Office of Foreign Assets Control, the United
Nations Security Council, the European Union, His Majesty’s Treasury, or other relevant sanctions authority (collectively, “Sanctions”);
or
(2) located,
organized, or resident in a country or territory that is the subject of Sanctions (including Burma/Myanmar, Cuba, Iran, North Korea, Sudan
and Syria).
(ii) The
Company represents and covenants that it will not, directly or indirectly, knowingly use, lend, contribute, or otherwise make available
the proceeds of the offering governed by this Agreement to any subsidiary, joint venture partner, or other director, officer, employee,
agent, affiliate, or representative of the Company:
(1) to
fund or facilitate any activities or business of or with any Person or in any country or territory that, at the time of such funding or
facilitation, is the subject of Sanctions; or
(2) in
any other manner that will result in a violation of Sanctions by any Person (including any Person participating in the offering, whether
as underwriter, advisor, investor, or otherwise).
(iii) Except
as detailed in the Prospectus, for the past five years, the Company has not knowingly engaged in, is not now knowingly engaged in, and
will not engage in, any dealings or transactions with any Person, or in any country or territory, that at the time of the dealing or transaction
is or was the subject of Sanctions.
(rr) Stock
Transfer Taxes. On each Settlement Date, all stock transfer or other taxes (other than income taxes) that are required to be paid
in connection with the sale and transfer of the Placement Shares to be sold hereunder will be, or will have been, fully paid or provided
for by the Company and all laws imposing such taxes will be or will have been fully complied with in all material respects.
Any certificate signed by an
officer of the Company and delivered to the Agent or to counsel for the Agent pursuant to or in connection with this Agreement will be
deemed to be a representation and warranty by the Company, as applicable, to the Agent as to the matters set forth therein.
7. Covenants
of the Company. The Company covenants and agrees with the Agent that:
(a) Registration
Statement Amendments. After the date of this Agreement and during any period in which a Prospectus relating to any Placement Shares
is required to be delivered by the Agent under the Securities Act (including in circumstances when such requirement may be satisfied pursuant
to Rule 172 under the Securities Act): (i) the Company will notify the Agent promptly of the time when any subsequent amendment to
the Registration Statement, other than documents incorporated by reference, has been filed with the SEC and/or has become effective or
any subsequent supplement to the Prospectus has been filed and of any request by the SEC for any amendment or supplement to the Registration
Statement or Prospectus or for additional information; (ii) the Company will prepare and file with the SEC, promptly upon the Agent’s
reasonable request, any amendments or supplements to the Registration Statement or Prospectus that, in the Agent’s reasonable opinion,
may be necessary or advisable in connection with the distribution of the Placement Shares by the Agent (provided, however, that
the failure of the Agent to make such request will not relieve the Company of any obligation or liability hereunder,
or affect the Agent’s
right to rely on the representations and warranties made by the Company in this Agreement and provided, further, that the only remedy
the Agent will have respecting the failure to make such filing will be to cease making sales under this Agreement until such amendment
or supplement is filed); (iii) the Company will not file any amendment or supplement to the Registration Statement or Prospectus
relating to the sale of Placement Shares or a security convertible into the Placement Shares unless a copy thereof has been submitted
to the Agent within a reasonable period of time before the filing and the Agent has not reasonably objected thereto within two (2) Business
Days (provided, however, that (A) the failure of the Agent to make such objection will not relieve the Company of any obligation
or liability hereunder, or affect the Agent’s right to rely on the representations and warranties made by the Company in this Agreement
and provided, further, that the only remedy the Agent will have respecting the failure by the Company to provide the Agent with such copy
will be to cease making sales under this Agreement and (B) the Company will have no obligation to provide the Agent any advance copy of
such filing or provide to the Agent an opportunity to object to such filing if (i) the filing does not name the Agent and does not relate
to the transactions pursuant hereto or (ii) relates to the termination of this Agreement or the Prospectus Supplement) and the Company
will furnish to the Agent at the time of filing thereof a copy of any document that upon filing is deemed to be incorporated by reference
into the Registration Statement or Prospectus, except for those documents available via EDGAR; and (iv) the Company will cause each
amendment or supplement to the Prospectus to be filed with the SEC as required pursuant to the applicable paragraph of Rule 424(b) of
the Securities Act or, in the case of any document to be incorporated therein by reference, to be filed with the SEC as required pursuant
to the Exchange Act, within the period prescribed (the determination to file or not file any amendment or supplement with the SEC under
this Section 7(a), based on the Company’s reasonable opinion or reasonable objections, will be made exclusively by the Company).
(b) Notice
of SEC Stop Orders. The Company will advise the Agent, promptly after it receives notice or obtains knowledge thereof, of the issuance
or threatened issuance by the SEC of any stop order suspending the effectiveness of the Registration Statement, of the suspension of the
qualification of the Placement Shares for offering or sale in any jurisdiction, or of the initiation or threatening of any proceeding
for any such purpose; and it will promptly use its commercially reasonable efforts to prevent the issuance of any stop order or to obtain
its withdrawal if such a stop order should be issued. The Company will advise the Agent promptly after it receives any request by the
SEC for any amendments to the Registration Statement or any amendment or supplements to the Prospectus or any Issuer Free Writing Prospectus
or for additional information related to the offering of the Placement Shares or for additional information related to the Registration
Statement, the Prospectus or any Issuer Free Writing Prospectus in connection with the offering of the Placement Shares.
(c) Delivery
of Prospectus; Subsequent Changes. During any period in which a Prospectus relating to the Placement Shares is required to be delivered
by the Agent under the Securities Act respecting the offer and sale of the Placement Shares (including in circumstances where such requirement
may be satisfied pursuant to Rule 172 under the Securities Act) (the “Prospectus Delivery Period”), the Company will
comply with all requirements imposed upon it by the Securities Act, as from time to time in force, and to file on or before its due dates
all reports and any definitive proxy or information statements required to be filed by the Company with the SEC pursuant to Sections 13(a),
13(c), 14, 15(d), or any other provision of or under the Exchange Act. If the Company has omitted any information from the Registration
Statement pursuant to Rule 430A under the Securities Act, it will use its commercially reasonable efforts to comply with the provisions
of and make all requisite filings with the SEC pursuant to said Rule 430A and to notify the Agent promptly of all such filings. If during
the Prospectus Delivery Period any event occurs as a result of which the Prospectus as then amended or supplemented would include an untrue
statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances
then existing, not misleading, or if during the Prospectus Delivery Period it is necessary to amend or supplement the Registration Statement
or Prospectus to comply with the Securities Act, the Company will promptly notify the Agent to suspend the offering of Placement Shares
during such period and the Company will promptly amend or supplement the Registration Statement or Prospectus (at the expense of the Company)
so as to correct such statement or omission or effect such compliance; provided, however, that the Company may delay any amendment or
supplement, if in the sole discretion of the Company, it is in the Company’s best interest to do so.
(d) Listing
of Placement Shares. During the Prospectus Delivery Period, the Company will use its commercially reasonable efforts to cause the
Placement Shares to be listed on the Exchange.
(e) Delivery
of Registration Statement and Prospectus. The Company will furnish to the Agent and its counsel (at the expense of the Company) copies
of the Registration Statement, the Prospectus (including all documents incorporated by reference therein) and all amendments and supplements
to the Registration Statement or Prospectus that are filed with the SEC during the Prospectus Delivery Period (including all documents
filed with the SEC during such period that are deemed to be incorporated by reference therein), in each case as soon as reasonably practicable
and in such quantities as the Agent may from time to time reasonably request and, at the Agent’s request, will also furnish copies
of the Prospectus to each exchange or market on which sales of the Placement Shares may be made; provided, however, that the Company will
not be required to furnish any document (other than the Prospectus) to the Agent to the extent such document is available on EDGAR.
(f) Earnings
Statement. The Company will make generally available to its security holders as soon as practicable, but in any event not later than
15 months after the end of the Company’s current fiscal quarter, an earnings statement covering a 12-month period that satisfies
the provisions of Section 11(a) and Rule 158 of the Securities Act. The Company’s compliance with the reporting requirements of
the Exchange Act shall be deemed to satisfy this Section 7(f).
(g) Use
of Proceeds. The Company will use the Net Proceeds as described in the Prospectus in the section entitled “Use of Proceeds.”
(h) Notice
of Other Sales. Without the prior written notice to the Agent, the Company will not, directly or indirectly, offer to sell, sell,
contract to sell, grant any option to sell or otherwise dispose of any Common Stock (other than the Placement Shares offered pursuant
to this Agreement) or securities convertible into or exchangeable for Common Stock, warrants or any rights to purchase or acquire, Common
Stock during the period beginning on the second Trading Day immediately prior to the date on which any Placement Notice is delivered to
the Agent hereunder and ending on the fifth Trading Day immediately following the final Settlement Date respecting Placement Shares sold
pursuant to such Placement Notice (or, if the Placement Notice has been terminated or suspended prior to the sale of all Placement Shares
covered by a Placement Notice, the date of such suspension or termination); and will not directly or indirectly in any other “at-the-market”
offering sell, contract to sell, grant any option to sell or otherwise dispose of any Common Stock (other than the Placement Shares offered
pursuant to this Agreement) or securities convertible into or exchangeable for Common Stock, warrants or any rights to purchase or acquire,
Common Stock prior to the termination of this Agreement; provided, however, that such restrictions will not be required
in connection with the Company’s issuance or sale of: (1) Common Stock, options to purchase Common Stock or Common Stock issuable
upon the exercise of options or restricted stock units granted pursuant to any employee or director stock option or benefits plan, stock
ownership plan or dividend reinvestment plan (but not Common Stock subject to a waiver to exceed plan limits in its dividend reinvestment
plan) of the Company whether now in effect or hereafter implemented; (2) Common Stock issuable upon conversion of securities or in
respect of dividends accruing thereon or the exercise of warrants, options or other rights in effect or outstanding, and disclosed in
filings by the Company available on EDGAR or otherwise in writing to the Agent; and (3) Common Stock, or securities convertible into
or exercisable for Common Stock, as consideration for mergers, acquisitions, other business combinations, licensing agreements or strategic
alliances, or offered and sold in a privately negotiated transaction to vendors, customers, or strategic partners and otherwise conducted
in a manner so as not to be integrated with the offering of Common Stock hereby.
(i) Change
of Circumstances. The Company will, at any time that a Placement Notice has been issued, advise the Agent promptly after it will have
received notice or obtained knowledge thereof, of any information or fact that would alter or affect in any material respect any opinion,
certificate, letter or other document required to be provided to the Agent pursuant to this Agreement.
(j) Due
Diligence Cooperation. The Company will cooperate with any reasonable due diligence review conducted by the Agent or its representatives
in connection with the transactions contemplated hereby, including providing information and making available documents and senior corporate
officers, during regular business hours and at the Company’s principal offices or such other location mutually agreed to by the
parties, as the Agent may reasonably request.
(k) Disclosure
of Shares Sold. The Company will disclose information regarding the sale of the Placement Shares in compliance with the requirements
of the Exchange Act.
(l) Representation
Dates; Certificate. On the date of this Agreement and each time the Company:
(i) files
the Prospectus relating to the Placement Shares or amends or supplements (other than a prospectus supplement relating solely to an offering
of securities other than the Placement Shares) the Registration Statement or the Prospectus relating to the Placement Shares by means
of a post-effective amendment, sticker, or supplement but not by means of incorporation of documents by reference into the Registration
Statement or the Prospectus relating to the Placement Shares;
(ii) files
an annual report on Form 10-K under the Exchange Act (including any Form 10-K/A that contains restated financial statements);
(iii) files
a quarterly report on Form 10-Q under the Exchange Act; or
(iv) files
a current report on Form 8-K containing amended audited financial information (other than information “furnished” pursuant
to Items 2.02 or 7.01 of Form 8-K or to provide disclosure pursuant to Item 8.01 of Form 8-K relating to the reclassification of
certain properties as discontinued operations in accordance with Statement of Financial Accounting Standards No. 144) under the Exchange
Act (each date of filing of one or more of the documents referred to in clauses (i) through (iv) will be a “Representation Date”);
the Company will furnish
the Agent (but in the case of clause (iv) above only if the Agent reasonably determines that the information contained in such Form 8-K
is material) with a certificate, in the form attached hereto as Exhibit A. The requirement to provide a certificate under this
Section 7(l) will be waived for any Representation Date occurring at a time at which no Placement Notice is pending, which waiver will
continue until the earlier to occur of the date the Company delivers a Placement Notice hereunder (which for such calendar quarter will
be considered a Representation Date) and the next occurring Representation Date. Notwithstanding the foregoing, if the Company subsequently
decides to sell Placement Shares following a Representation Date when the Company relied on such waiver and did not provide the Agent
with a certificate under this Section 7(l), then before the Company delivers the Placement Notice or the Agent sells any Placement Shares,
the Company will provide the Agent with a certificate, in the form attached hereto as Exhibit A, dated the date of the Placement
Notice.
(m) Legal
Opinion. On the date of this Agreement and within five Trading Days of each Representation Date for which the Company is obligated
to deliver a certificate in the form attached hereto as Exhibit A for which no waiver is applicable, the Company will cause to
be furnished to the Agent written opinions of Olshan Frome Wolosky LLP (“Company Counsel”), or other counsel reasonably
satisfactory to the Agent, in form and substance reasonably satisfactory to the Agent and its counsel; provided, however,
the Company will be required to furnish to the Agent no more than one opinion hereunder per calendar quarter; provided, further,
that in lieu of such opinions for subsequent periodic filings under the Exchange Act, Company Counsel may furnish the Agent with a letter
(a “Reliance Letter”) to the effect that the Agent may rely on a prior opinion delivered under this Section 7(m)
to the same extent as if it were dated the date of such letter (except that statements in such prior opinion will be deemed to relate
to the Registration Statement and the Prospectus as amended or supplemented as of the date of the Reliance Letter).
(n) Comfort
Letters. On the date of this Agreement and within five Trading Days of each Representation Date, other than pursuant to Section
7(l)(iii), for which the Company is obligated to deliver a certificate in the form attached hereto as Exhibit A for which no
waiver is applicable, the Company will cause its Accountant to furnish the Agent a letter (the “Comfort Letter”) with
respect to the Company’s financial statements for its fiscal year ended April 30, 2024, dated the date the Comfort Letter is delivered,
which will meet the requirements set forth in this Section 7(n). The Comfort Letter from the Accountant will be in a form and substance
reasonably satisfactory to the Agent: (i) confirming that it is an independent public accounting firm within the meaning of the Securities
Act and the PCAOB; (ii) stating, as of such date, the conclusions and findings of such firm respecting the financial information
and other matters ordinarily covered by accountants’ “comfort letters” to underwriters in connection with registered
public offerings (the first such letter, the “Initial Comfort Letter”); and (iii) updating the Initial Comfort
Letter with any information that would have been included in the Initial Comfort Letter had it been given on such date and modified as
necessary to relate to the Registration Statement and the Prospectus, as amended and supplemented to the date of such letter.
(o) Market
Activities. The Company will not, directly or indirectly: (i) take any action designed to cause or result in, or that constitutes
or might reasonably be expected to constitute, the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of Common Stock; or (ii) sell, bid for, or purchase Common Stock in violation of Regulation M, or pay anyone any
compensation for soliciting purchases of the Placement Shares other than the Agent.
(p) Investment
Company Act. The Company will conduct its affairs in such a manner so as to reasonably ensure that it will not be or become, at any
time prior to the termination of this Agreement, required to register as an “investment company,” as such term is defined
in the Investment Company Act.
(q) No
Offer to Sell. Other than an Issuer Free Writing Prospectus approved in advance by the Company and the Agent in its capacity as agent
hereunder, neither the Agent nor the Company (including its agents and representatives, other than the Agent in its capacity as such)
will make, use, prepare, authorize, approve, or refer to any written communication (as defined in Rule 405 under the Securities Act),
required to be filed with the SEC, that constitutes an offer to sell or solicitation of an offer to buy Placement Shares hereunder.
(r) Sarbanes-Oxley
Act. The Company shall comply with the applicable provisions of the Sarbanes-Oxley Act in all material respects.
8. Representations
and Covenants of the Agent. The Agent represents and warrants that it is duly registered as a broker-dealer under FINRA, the Exchange
Act, and the applicable statutes and regulations of each state in which the Placement Shares will be offered and sold, except such states
in which the Agent is exempt from registration or such registration is not otherwise required. The Agent will continue, for the term of
this Agreement, to be duly registered as a broker-dealer under FINRA, the Exchange Act, and the applicable statutes and regulations of
each state in which the Placement Shares will be offered and sold, except such states in which the Agent is exempt from registration or
such registration is not otherwise required, during the term of this Agreement. The Agent will comply with all applicable law and regulations
in connection with the Placement Shares, including Regulation M.
9. Payment
of Expenses. The Company will pay all expenses incident to the performance of its obligations under this Agreement, including: (i) the
preparation, filing, including any fees required by the SEC, and printing of the Registration Statement (including financial statements
and exhibits) as originally filed and of each amendment and supplement thereto and each Free Writing Prospectus, in such number as the
Agent will reasonably deem necessary; (ii) the printing and delivery to the Agent of this Agreement and such other documents as may reasonably
be required in connection with the offering, purchase, sale, issuance, or delivery of the Placement Shares; (iii) the preparation,
issuance, and delivery of the certificates, if any, for the Placement Shares to the Agent, including any stock or other transfer taxes
and any capital duties, stamp duties, or other duties or taxes payable upon the sale, issuance, or delivery of the Placement Shares to
the Agent; (iv) the fees and disbursements of the counsel, accountants, and other advisors to the Company; (v) the fees and
expenses of the transfer agent and registrar for the Common Stock; (vi) the filing fees incident to any review by FINRA of the terms
of the sale of the Placement Shares; (vii) the fees and expenses incurred in connection with the listing of the Placement Shares
on the Exchange; (viii) usual and customary transaction, ticket, and similar charges; (ix) $30,000 in due diligence fees and expenses
of the Agent, including Agent’s legal counsel initially and, thereafter, the reasonable fees and expenses of the Agent’s legal
counsel in connection with quarterly and annual bring-downs required hereunder up to a maximum amount of $2,500 for each such bring-down.
10. Conditions
to the Agent’s Obligations. The obligations of the Agent hereunder respecting a Placement will be subject to the continuing
accuracy and completeness of the representations and warranties made by the Company herein in all material respects (except for representations
and warranties qualified by materiality which are required to be accurate and complete in all respects), to the due performance by the
Company of its obligations hereunder in all material respects, to the completion by the Agent of a due diligence review satisfactory to
it in its reasonable judgment, and to the continuing satisfaction (or waiver by the Agent in its sole discretion) of the following additional
conditions:
(a) Registration
Statement Effective. The Company shall at all times maintain in effect the Registration Statement, which will be available for the
sale of all Placement Shares contemplated to be issued by any Placement Notice.
(b) No
Material Notices. None of the following events will have occurred and be continuing: (i) receipt by the Company of any request
for additional information from the SEC or any other federal or state governmental authority during the period of effectiveness of the
Registration Statement the response to which would require any post-effective amendments or supplements to the Registration Statement
or the Prospectus which have not, as of the time of such Placement, been so made; (ii) the issuance by the SEC or any other federal
or state governmental authority of any stop order suspending the effectiveness of the Registration Statement or the initiation of any
proceedings for that purpose; (iii) receipt by the Company of any notification respecting the suspension of the qualification or
exemption from qualification of any of the Placement Shares for sale in any jurisdiction or the initiation or threatening of any proceeding
for such purpose; or (iv) the occurrence of any event that requires the making of any changes in the Registration Statement, the
Prospectus or documents so that, in the case of the Registration Statement, it will not contain any materially untrue statement of a material
fact or omit to state any material fact required to be stated therein or necessary to make the statements therein not misleading and,
that in the case of the Prospectus, it will not contain any materially untrue statement of a material fact or omit to state any material
fact required to be stated therein or necessary to make the statements therein, in the light of the circumstances under which they were
made, not misleading.
(c) No
Misstatement or Material Omission. The Agent will not have advised the Company that the Registration Statement or Prospectus, or any
amendment or supplement thereto, contains an untrue statement of fact that in the Agent’s reasonable opinion is material, or omits
to state a fact that in the Agent’s opinion is material and is required to be stated therein or is necessary to make the statements
therein not misleading, which changes shall not, as of the time of the Placement, have been so made.
(d) Material
Changes. Except as contemplated in the Prospectus, or disclosed in the Company’s reports filed with the SEC, there will not
have been any material adverse change, on a consolidated basis, in the authorized capital stock of the Company or any Material Adverse
Effect, or any development that could reasonably be expected to cause a Material Adverse Effect.
(e) Legal
Opinion. The Agent will have received the opinion of Company Counsel required to be delivered pursuant Section 7(m) on or before
the date on which such delivery of such opinion is required pursuant to Section 7(m).
(f) Comfort
Letter. The Agent will have received the Comfort Letter required to be delivered pursuant Section 7(n) on or before the date
on which such delivery of such letter is required pursuant to Section 7(n).
(g) Representation
Certificate. The Agent will have received the certificate required to be delivered pursuant to Section 7(l) on or before the
date on which delivery of such certificate is required pursuant to Section 7(l).
(h) No
Suspension. Trading in the Common Stock will not have been suspended on the Exchange and the Common Stock will not have been delisted
from the Exchange.
(i) Other
Materials. On each date on which the Company is required to deliver a certificate pursuant to Section 7(l), the Company will
have furnished to the Agent such appropriate further information, certificates, and documents as the Agent may reasonably request and
that are usually and customarily furnished by an issuer of securities in connection with a securities offering. All such opinions, certificates,
letters, and other documents will be in compliance with the provisions hereof. The Company will furnish the Agent with such conformed
copies of such opinions, certificates, letters, and other documents as the Agent will reasonably request.
(j) Securities
Act Filings Made. All filings with the SEC required by Rule 424 under the Securities Act to have been filed prior to the issuance
of any Placement Notice hereunder will have been made within the applicable period prescribed for such filing by Rule 424.
(k) Approval
for Listing. To the extent required by continued listing rules of the Exchange, the Placement Shares will either have been approved
for listing on the Exchange, subject only to notice of issuance, or the Company will have filed an application for listing of the Placement
Shares on the Exchange at, or prior to, the issuance of any Placement Notice.
(l) No
Termination Event. No event will have occurred that would permit the Agent to terminate this Agreement pursuant to Section 13(a).
11. Indemnification
and Contribution.
(a) Company
Indemnification. The Company agrees to indemnify and hold harmless the Agent, its partners, members, directors, officers, employees,
and agents and each Person, if any, who controls any Agent within the meaning of Section 15 of the Securities Act or Section 20
of the Exchange Act as follows:
(i) against
any and all loss, liability, claim, damage, and expense whatsoever, as incurred, joint or several, arising out of or based upon any untrue
statement or alleged untrue statement of a material fact contained in the Registration Statement (or any amendment thereto), or the omission
or alleged omission therefrom of a material fact required to be stated therein or necessary to make the statements therein not misleading,
or arising out of any untrue statement or alleged untrue statement of a material fact included in any related Issuer Free Writing Prospectus
or the Prospectus (or any amendment or supplement thereto), or the omission or alleged omission therefrom of a material fact necessary
in order to make the statements therein, in the light of the circumstances under which they were made, not misleading;
(ii) against
any and all loss, liability, claim, damage and expense whatsoever, as incurred, joint or several, to the extent of the aggregate amount
paid in settlement of any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened,
or of any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission; provided
that any such settlement is effected with the written consent of the Company, which consent will not unreasonably be delayed or withheld;
and
(iii) against
any and all expense whatsoever, as incurred (including the reasonable fees and disbursements of counsel), reasonably incurred in investigating,
preparing or defending against any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened,
or any claim whatsoever based upon any such untrue statement or omission, or any such alleged untrue statement or omission, to the extent
that any such expense is not paid under (i) or (ii) above;
provided,
however, that this indemnity agreement will not apply to any loss, liability, claim, damage, or expense to the extent arising
out of any untrue statement or omission or alleged untrue statement or omission made solely in reliance upon and in conformity with written
information furnished to the Company by the Agent expressly for use in the Registration Statement (or any amendment thereto), or in any
related Issuer Free Writing Prospectus or the Prospectus (or any amendment or supplement thereto).
(b) Agent
Indemnification. The Agent agrees, jointly and severally, to indemnify and hold harmless the Company and its directors and each officer
of the Company who signed the Registration Statement, and each Person, if any, that: (i) controls the Company within the meaning
of Section 15 of the Securities Act or Section 20 of the Exchange Act; or (ii) is controlled by or is under common control with the
Company against any and all loss, liability, claim, damage, and expense described in the indemnity contained in Section 11(c),
as incurred, but only respecting untrue statements or omissions, or alleged untrue statements or omissions, made in the Registration Statement
(or any amendments thereto), the Prospectus (or any amendment or supplement thereto) or any Free Writing Prospectus in reliance upon and
in conformity with information furnished to the Company in writing by the Agent expressly for use therein.
(c) Procedure.
(i) Any
party that proposes to assert the right to be indemnified under this Section 11 will, promptly after receipt of notice of commencement
of any action against such party in respect of which a claim is to be made against an indemnifying party or parties under this Section
11, notify each such indemnifying party of the commencement of such action, enclosing a copy of all papers served, but the omission
so to notify such indemnifying party will not relieve the indemnifying party from: (1) any liability that it might have to any indemnified
party otherwise than under this Section 11; and (2) any liability that it may have to any indemnified party under the foregoing
provision of this Section 11 unless, and only to the extent that, such omission results in the forfeiture or material impairment
of substantive rights or defenses by the indemnifying party.
(ii) If
any such action is brought against any indemnified party and it notifies the indemnifying party of its commencement, the indemnifying
party will be entitled to participate in and, to the extent that it elects by delivering written notice to the indemnified party promptly
after receiving notice of the commencement of the action from the indemnified party, jointly with any other indemnifying party similarly
notified, to assume the defense of the action, with counsel reasonably satisfactory to the indemnified party, and after notice from the
indemnifying party to the indemnified party of its election to assume the defense, the indemnifying party will not be liable to the indemnified
party for any legal or other expenses except as provided below and except for the reasonable costs of investigation subsequently incurred
by the indemnified party in connection with the defense.
(iii) The
indemnified party will have the right to employ its own counsel in any such action, but the fees, expenses and other charges of such counsel
will be at the expense of such indemnified party unless: (1) the employment of counsel by the indemnified party has been authorized
in writing by the indemnifying party; (2) the indemnified party has reasonably concluded (based on advice of counsel) that there
may be legal defenses available to it or other indemnified parties that are different from or in addition to those available to the indemnifying
party; (3) a conflict or potential conflict exists (based on advice of counsel to the indemnified party) between the indemnified
party and the indemnifying party (in which case the indemnifying party will not have the right to direct the defense of such action on
behalf of the indemnified party); or (4) the indemnifying party has not in fact employed counsel to assume the defense of such action
within a reasonable time after receiving notice of the commencement of the action, in each of which cases the reasonable fees, disbursements
and other charges of counsel will be at the expense of the indemnifying party or parties.
(iv) It
is understood that the indemnifying party or parties will not, in connection with any proceeding or related proceedings in the same jurisdiction,
be liable for the reasonable fees, disbursements and other charges of more than one separate firm admitted to practice in such jurisdiction
at any one time for all such indemnified party or parties. All such fees, disbursements, and other charges will be reimbursed by the indemnifying
party promptly after the indemnifying party receives a written invoice relating to fees, disbursements and other charges in reasonable
detail.
(v) An
indemnifying party will not, in any event, be liable for any settlement of any action or claim effected without its written consent. No
indemnifying party will, without the prior written consent of each indemnified party, settle or compromise or consent to the entry of
any judgment in any pending or threatened claim, action, or proceeding relating to the matters contemplated by this Section 11
(whether or not any indemnified party is a party thereto), unless such settlement, compromise or consent: (i) includes an unconditional
release of each indemnified party from all liability arising out of such litigation, investigation, proceeding, or claim; and (ii) does
not include a statement as to or an admission of fault, culpability, or a failure to act by or on behalf of any indemnified party.
(d) Contribution.
In order to provide for just and equitable contribution in circumstances in which the indemnification provided for in the foregoing paragraphs
of this Section 11 is applicable in accordance with its terms but for any reason is held to be unavailable from the Company or
the Agent, the Company and the Agent will contribute to the total losses, claims, liabilities, expenses, and damages (including any investigative,
legal and other expenses reasonably incurred in connection with, and any amount paid in settlement of, any action, suit or proceeding
or any claim asserted, but after deducting any contribution received by the Company from Persons other than the Agent, such as Persons
that control the Company within the meaning of the Securities Act, officers of the Company who signed the Registration Statement and directors
of the Company, who also may be liable for contribution) to which the Company and the Agent may be subject in such proportion as is appropriate
to reflect the relative benefits received by the Company, on the one hand, and the Agent, on the other hand. The relative benefits received
by the Company, on the one hand, and the Agent, on the other hand, will be deemed to be in the same proportion as the total net proceeds
from the sale of the Placement Shares (before deducting expenses) received by the Company bear to the total compensation received by the
Agent (before deducting expenses) from the sale of Placement Shares on behalf of the Company. If, but only if, the allocation provided
by the foregoing sentence is not permitted by applicable law, the
allocation of contribution will be made in such proportion as is appropriate
to reflect not only the relative benefits referred to in the foregoing sentence but also the relative fault of the Company, on the one
hand, and the Agent, on the other hand, respecting the statements or omission that resulted in such loss, claim, liability, expense or
damage, or action in respect thereof, as well as any other relevant equitable considerations respecting such offering. Such relative fault
will be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or omission
or alleged omission to state a material fact relates to information supplied by the Company or the Agent, the intent of the parties and
their relative knowledge, access to information and opportunity to correct or prevent such statement or omission. The Company and the
Agent agree that it would not be just and equitable if contributions pursuant to this Section 11(d) were to be determined by pro
rata allocation or by any other method of allocation that does not take into account the equitable considerations referred to herein.
The amount paid or payable by an indemnified party as a result of the loss, claim, liability, expense, or damage, or action in respect
thereof, referred to above in this Section 11(d) will be deemed to include, for the purpose of this Section 11(d), any legal
or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim
to the extent consistent with Section 11(c) hereof. Notwithstanding the foregoing provisions of this Section 11(d), the Agent will
not be required to contribute any amount in excess of the commissions received by it under this Agreement and no Person found guilty of
fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person
who was not guilty of such fraudulent misrepresentation. For purposes of this Section 11(d), any Person who controls a party to
this Agreement within the meaning of the Securities Act, and any officers, directors, partners, employees or agents of the Agent, will
have the same rights to contribution as that party, and each officer and director of the Company who signed the Registration Statement
will have the same rights to contribution as the Company, subject in each case to the provisions hereof. Any party entitled to contribution,
promptly after receipt of notice of commencement of any action against such party in respect of which a claim for contribution may be
made under this Section 11(d), will notify any such party or parties from whom contribution may be sought, but the omission to
so notify will not relieve that party or parties from whom contribution may be sought from any other obligation it or they may have under
this Section 11(d) except to the extent that the failure to so notify such other party materially prejudiced the substantive rights
or defenses of the party from whom contribution is sought. Except for a settlement entered into pursuant to the last sentence of Section
11(c) hereof, no party will be liable for contribution respecting any action or claim settled without its written consent if such
consent is required pursuant to Section 11(c) hereof.
12. Representations
and Agreements to Survive Delivery. The indemnity and contribution agreements contained in Section 11 of this Agreement and
all representations and warranties of the Company herein or in certificates delivered pursuant hereto will survive, as of its dates, regardless
of: (a) any investigation made by or on behalf of the Agent, any controlling Persons, or the Company (or any of its officers, directors,
or controlling Persons); (b) delivery and acceptance of the Placement Shares and payment therefor; or (c) any termination of
this Agreement.
13. Termination.
(a) The
Agent may terminate this Agreement, by written notice to the Company, as hereinafter specified at any time: (i) if there has been,
since the time of execution of this Agreement or since the date as of which information is given in the Prospectus, any Material Adverse
Effect, or any development has occurred that is reasonably likely to have a Material Adverse Effect or in the reasonable judgment of the
Agent makes it impractical or inadvisable to market the Placement Shares or to enforce contracts for the sale of the Placement Shares;
(ii) if there has occurred any material adverse change in the financial markets in the United States or the international financial
markets, any outbreak of hostilities or escalation thereof or other calamity or crisis or any change or development involving a prospective
change in national or international political, financial or economic conditions, in each case the effect of which is such as to make it,
in the reasonable judgment of the Agent, impracticable or inadvisable to market the Placement Shares or to enforce contracts for the sale
of the Placement Shares; (iii) if trading in the Common Stock has been suspended or limited by the SEC or the Exchange, or if trading
generally on the Exchange has been suspended or limited, or minimum prices for trading have been fixed on the Exchange; (iv) if a
major disruption of securities settlements or clearance services in the United States will have occurred and be continuing; or (v) if
a banking moratorium has been declared by either U.S. Federal or New York authorities. Any such termination will be without liability
of any party to any other party except that the provisions of Section 9 (Expenses), Section 11 (Indemnification), Section
12 (Survival of Representations), Section 18 (Applicable Law; Waiver of Jury Trial), Section 19 (Consent to Jurisdiction),
and Section 20 (Use of Information) hereof will remain in full force and effect notwithstanding such termination. If the Agent
elects to terminate this Agreement as provided in this Section 13(a), the Agent will provide the required notice as specified in
Section 14 (Notices).
(b) (i) The Company
will have the right, by giving 10 days’ notice as hereinafter specified to terminate this Agreement in its sole discretion at any
time after the date of this Agreement.
(ii) If
the Agent declines any commercially reasonable placement notice pursuant to Section 2(a) of this Agreement, then the Company will
have the right to terminate this Agreement with respect to the Agent by giving written notice of termination to the Agent. Any such termination
will be effective immediately upon a delivery of a termination notice by the Company to the Agent.
Any termination
pursuant to Section 13(b) will be without liability of any party to any other party except that the provisions of Section 9,
Section 11, Section 12, Section 18, Section 19, and Section 20 hereof will remain in full force and
effect notwithstanding such termination.
(c) The
Agent will have the right, by giving 10 days’ notice as hereinafter specified to terminate this Agreement in its discretion at any
time after the date of this Agreement. Any such termination will be without liability of any party to any other party except that the
provisions of Section 9, Section 11, Section 12, Section 18, Section 19, and Section 20 hereof
will remain in full force and effect notwithstanding such termination.
(d) Unless
earlier terminated pursuant to this Section 13, this Agreement will automatically terminate upon the earlier to occur of: (i) the
two-year anniversary of the date hereof; or (ii) the issuance and sale of all of the Placement Shares through the Agent on the terms
and subject to the conditions set forth herein, except that, in either such case, the provisions of Section 9, Section 11,
Section 12, Section 18, Section 19, and Section 20 hereof will remain in full force and effect notwithstanding
such termination.
(e) This
Agreement will remain in full force and effect unless terminated pursuant to Sections 13(a), (b), (c), or (d)
above or otherwise by mutual agreement of the parties. Upon termination of this Agreement, the Company will not have any liability to
any Agent for any discount, commission, or other compensation respecting any Placement Shares not otherwise sold by an Agent under this
Agreement.
(f) Any
termination of this Agreement will be effective on the date specified in such notice of termination; provided, however,
that such termination will not be effective until the close of business on the date of receipt of such notice by the Agent or the Company,
as the case may be; provided further, that the Agent shall suspend any ongoing Placement as soon as practicable following receipt of the
notice of termination (and in any event by the close of business on the date of receipt). If such termination occurs prior to the Settlement
Date for any sale of Placement Shares, such Placement Shares will settle in accordance with the provisions of this Agreement.
14. Notices.
(a) All
notices or other communications required or permitted to be given by any party to any other party pursuant to the terms of this Agreement
will be in writing, unless otherwise specified, and if sent to Ascendiant Capital Markets, LLC, will be delivered to:
Ascendiant Capital Markets,
LLC
Attention: Managing
Partner
110 Front
Street, Suite 300
Jupiter, FL
33477
with a copy to:
Clyde Snow & Sessions,
P.C.
Attention: Brian Lebrecht
201 South Main Street,
Suite 2200
Salt Lake City, UT 84111
and if to the Company,
will be delivered to:
Alzamend Neuro, Inc.
3480 Peachtree Road
NE,
Second Floor, Suite
103
Atlanta, GA 30326
Attn: David J. Katzoff,
CFO
David@alzamend.com
with copies (which
shall not constitute notice) to:
Alzamend Neuro, Inc.
122 East 42nd Street,
50th Floor
New York, NY, 10168
Attn: Henry Nisser,
EVP and General Counsel
Henry@alzamend.com
and
Olshan Frome Wolosky
LLP
1325 Avenue of the Americas,
15th Floor
New York, NY 10019
Attn: Kenneth Schlesinger
kschlesinger@olshanlaw.com
Notice to any other Agent
shall be sent to its address set forth in Annex 1 hereto.
(b) Each
such notice or other communication will be deemed given: (i) when delivered personally on or before 4:30 p.m., New York City
time, on a Business Day or, if such day is not a Business Day, on the next succeeding Business Day; or (ii) on the next Business
Day after timely delivery to a nationally recognized overnight courier. For purposes of this Agreement, “Business Day”
will mean any day on which the Exchange and commercial banks in the City of New York are open for business. An Electronic Notice needs
to be sent for every communication between the parties to this Agreement.
(c) An
electronic communication (“Electronic Notice”) will be deemed written notice for purposes of this Section 14
if sent to the electronic mail address set forth above or specified by the receiving party under separate cover. Electronic Notice will
be deemed received at the time the party sending Electronic Notice receives confirmation of receipt by the receiving party. Any party
receiving Electronic Notice may request and will be entitled to receive the notice on paper, in a nonelectronic form (“Nonelectronic
Notice”), which will be sent to the requesting party within 10 days of receipt of the written request for Nonelectronic Notice.
(d) Each
party to this Agreement may change such address for notices by sending to the parties to this Agreement written notice of a new address
for such purpose.
15. Successors
and Assigns. This Agreement will inure to the benefit of and be binding upon the Company and the Agent and its successors and the
affiliates, controlling persons, partners, members, officers, directors, employees, and agents referred to in Section 11 hereof.
References to any of the parties contained in this Agreement will be deemed to include the successors and permitted assigns of such party.
Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or its successors and
permitted assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided
in this Agreement. Neither party may assign its rights or obligations under this Agreement without the prior written consent of the other
party.
16. Adjustments
for Stock Splits. The parties acknowledge and agree that all share-related numbers contained in this Agreement will be adjusted to
take into account any share consolidation, stock split, stock dividend, corporate domestication or similar event effected respecting the
Placement Shares.
17. Entire
Agreement; Amendment; Severability. This Agreement (including all schedules and exhibits attached hereto and Placement Notices issued
pursuant hereto), by and between the Company and the Agent constitutes the entire agreement of the parties respecting the subject matter
hereof and thereof and supersedes all other prior and contemporaneous agreements and undertakings, both written and oral, among the parties
hereto with regard to the subject matter hereof and thereof. Neither this Agreement nor any term hereof may be amended except pursuant
to a written instrument executed by the Company and the Agent. In the event that any one or more of the provisions contained herein, or
the application thereof in any circumstance, is held invalid, illegal, or unenforceable as written by a court of competent jurisdiction,
then such provision will be given full force and effect to the fullest possible extent that it is valid, legal, and enforceable, and the
remainder of the terms and provisions herein will be construed as if such invalid, illegal, or unenforceable term or provision was not
contained herein, but only to the extent that giving effect to such provision and the remainder of the terms and provisions hereof will
be in accordance with the intent of the parties as reflected in this Agreement.
18. APPLICABLE
LAW; WAIVER OF JURY TRIAL. THIS AGREEMENT WILL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT
REGARD TO THE PRINCIPLES OF CONFLICTS OF LAWS. SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME. THE COMPANY HEREBY IRREVOCABLY WAIVES,
TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING
TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY.
19. CONSENT
TO JURISDICTION. EACH PARTY HEREBY IRREVOCABLY SUBMITS TO THE NON-EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN
THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH ANY TRANSACTION CONTEMPLATED
HEREBY, AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY
SUBJECT TO THE JURISDICTION OF ANY SUCH COURT, THAT SUCH SUIT, ACTION OR PROCEEDING IS BROUGHT IN AN INCONVENIENT FORUM OR THAT THE VENUE
OF SUCH SUIT, ACTION OR PROCEEDING IS IMPROPER. EACH PARTY HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS
BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF (CERTIFIED OR REGISTERED MAIL, RETURN RECEIPT REQUESTED)
TO SUCH PARTY AT THE ADDRESS IN EFFECT FOR NOTICES TO IT UNDER THIS AGREEMENT AND AGREES THAT SUCH SERVICE WILL CONSTITUTE GOOD AND SUFFICIENT
SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN WILL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER
PERMITTED BY LAW.
20. Use
of Information. The Agent may not use or disclose any information gained in connection with this Agreement and the transactions contemplated
by this Agreement, including due diligence, for any purpose except in connection with entering into this Agreement and providing services
as distribution agent hereunder.
21. Counterparts.
This Agreement may be executed in two or more counterparts, each of which will be deemed an original, but all of which together will constitute
one and the same instrument. Delivery of an executed Agreement by one party to the other may be made by facsimile transmission.
22. Effect
of Headings. The section and exhibit headings herein are for convenience only and will not affect the construction hereof.
23. Permitted
Free Writing Prospectuses. The Company represents, warrants, and agrees that, unless it obtains the prior consent of the Agent, which
consent shall not be unreasonably withheld, conditioned or delayed, and the Agent represents, warrants and agrees that, unless it obtains
the prior consent of the Company, which consent shall not be unreasonably withheld, conditioned or delayed, it has not made and will not
make any offer relating to the Placement Shares that would constitute an Issuer Free Writing Prospectus, or that would otherwise constitute
a “free writing prospectus,” as defined in Rule 405, required to be filed with the SEC. Any such free writing prospectus
consented to by the Agent or by the Company, as the case may be, is hereinafter referred to as a “Permitted Free Writing Prospectus.”
The Company represents and warrants that it has treated and agrees that it will treat each Permitted Free Writing Prospectus as an “issuer
free writing prospectus,” as defined in Rule 433, and has complied and will comply with the requirements of Rule 433 applicable
to any Permitted Free Writing Prospectus, including timely filing with the SEC where required, legending, and recordkeeping. For the purposes
of clarity, the parties hereto agree that all free writing prospectuses, if any, listed in Exhibit B hereto are Permitted
Free Writing Prospectuses.
24. Absence
of Fiduciary Relationship. The Company acknowledges and agrees that:
(a) The
Agent is acting solely as agent in connection with the public offering of the Placement Shares and in connection with each transaction
contemplated by this Agreement and the process leading to such transactions, and no fiduciary or advisory relationship between the Company
or any of its respective affiliates, stockholders (or other equity holders), creditors or employees or any other party, on the one hand,
and the Agent, on the other hand, has been or will be created in respect of any of the transactions contemplated by this Agreement, irrespective
of whether or not the Agent has advised or is advising the Company on other matters, and the Agent has no obligation to the Company respecting
the transactions contemplated by this Agreement except the obligations expressly set forth in this Agreement;
(b) it
is capable of evaluating and understanding, and understands and accepts, the terms, risks and conditions of the transactions contemplated
by this Agreement;
(c) the
Agent has not provided any legal, accounting, regulatory or tax advice respecting the transactions contemplated by this Agreement and
it has consulted its own legal, accounting, regulatory and tax advisors to the extent it has deemed appropriate;
(d) it
is aware that the Agent and its affiliates are engaged in a broad range of transactions that may involve interests that differ from those
of the Company and the Agent has no obligation to disclose such interests and transactions to the Company by virtue of any fiduciary,
advisory or agency relationship or otherwise; provided that the Agent hereby agrees not to engage in any such transaction that would cause
its interests to be in direct conflict with the best interests of the Company; and
(e) it
waives, to the fullest extent permitted by law, any claims it may have against any Agent for breach of fiduciary duty or alleged breach
of fiduciary duty in connection with the sale of Placement Shares under this Agreement and agrees that no Agent will have any liability
(whether direct or indirect, in contract, tort or otherwise) to it in respect of such a fiduciary duty claim or to any Person asserting
a fiduciary duty claim on its behalf or in right of it or the Company, employees or creditors of Company, other than in respect of the
Agent’s obligations under this Agreement and to keep information provided by the Company to the Agent’s and the Agents’
counsel confidential to the extent not otherwise publicly available.
25. Definitions.
As used in this Agreement, the following terms have the respective meanings set forth below:
(a) “Applicable
Time” means: (i) each Representation Date; and (ii) the time of each sale of any Placement Shares pursuant to this
Agreement.
(b) “Company’s
knowledge,” “knowledge of the Company” and similar expressions mean the actual knowledge of an executive
officer of the Company as of the date to which the expression relates.
(c) “Agent”
means, as of any given time, an Agent that the Company has designated as sales agent to sell Placement Shares pursuant to the terms of
this Agreement, which shall initially be Ascendiant Capital Markets, LLC.
(d) “Issuer
Free Writing Prospectus” means any “issuer free writing prospectus,” as defined in Rule 433, relating to the
Placement Shares.
(e) “Rule
164,” “Rule 172,” “Rule 405,” “Rule 415,” “Rule 424,”
“Rule 424(b),” “Rule 430A,” “Rule 430B,” and “Rule 433”
refer to such rules under the Securities Act Regulations.
(f) All
references in this Agreement to financial statements and schedules and other information that is “contained,” “included,”
or “stated” in the Registration Statement or the Prospectus (and all other references of like import) will be deemed to mean
and include all such financial statements and schedules and other information that is incorporated by reference in the Registration Statement
or the Prospectus, as the case may be.
(g) All
references in this Agreement to the Registration Statement, the Prospectus or any amendment or supplement to any of the foregoing will
be deemed to include the copy filed with the SEC pursuant to EDGAR; all references in this Agreement to any Issuer Free Writing Prospectus
(other than any Issuer Free Writing Prospectuses that, pursuant to Rule 433, are not required to be filed with the SEC) will be deemed
to include the copy thereof filed with the SEC pursuant to EDGAR; and all references in this Agreement to “supplements” to
the Prospectus will include any supplements, “wrappers,” or similar materials prepared in connection with any offering, sale,
or private placement of any Placement Shares by Ascendiant outside of the United States.
[Signature Page Follows]
If the foregoing correctly
sets forth the understanding between the Company and the Agent, please so indicate in the space provided below for that purpose, whereupon
this letter will constitute a binding agreement between the Company and the Agent.
| |
ALZAMEND NEURO, INC.
|
| |
|
| |
|
| |
|
| |
By: |
|
| |
Name: |
David J. Katzoff |
| |
Title: |
Chief Financial Officer |
ACCEPTED as of the date first-above
written:
| |
ASCENDIANT CAPITAL MARKETS, LLC
|
| |
|
| |
|
| |
|
| |
By: |
|
| |
Name: |
Bradley J. Wilhite |
| |
Title: |
Managing Partner |
22
v3.24.3
Cover
|
Oct. 03, 2024 |
| Cover [Abstract] |
|
| Document Type |
8-K
|
| Amendment Flag |
false
|
| Document Period End Date |
Oct. 03, 2024
|
| Entity File Number |
001-40483
|
| Entity Registrant Name |
ALZAMEND NEURO, INC.
|
| Entity Central Index Key |
0001677077
|
| Entity Tax Identification Number |
81-1822909
|
| Entity Incorporation, State or Country Code |
DE
|
| Entity Address, Address Line One |
3480 Peachtree Road NE
|
| Entity Address, Address Line Two |
Second Floor
|
| Entity Address, Address Line Three |
Suite
103
|
| Entity Address, City or Town |
Atlanta
|
| Entity Address, State or Province |
GA
|
| Entity Address, Postal Zip Code |
30326
|
| City Area Code |
(844)
|
| Local Phone Number |
722-6333
|
| Written Communications |
false
|
| Soliciting Material |
false
|
| Pre-commencement Tender Offer |
false
|
| Pre-commencement Issuer Tender Offer |
false
|
| Title of 12(b) Security |
Common Stock, $0.0001 par value
|
| Trading Symbol |
ALZN
|
| Security Exchange Name |
NASDAQ
|
| Entity Emerging Growth Company |
true
|
| Elected Not To Use the Extended Transition Period |
false
|
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 2 such as Street or Suite number
| Name: |
dei_EntityAddressAddressLine2 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 3 such as an Office Park
| Name: |
dei_EntityAddressAddressLine3 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14a
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
Alzamend Neuro (NASDAQ:ALZN)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
Alzamend Neuro (NASDAQ:ALZN)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024
